Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,563 | 398 | 86.8% |
| Consulting Fee | $750.00 | 1 | 8.6% |
| Education | $404.35 | 10 | 4.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $3,183 | 93 | $0 (2024) |
| Gilead Sciences, Inc. | $1,124 | 63 | $0 (2024) |
| Janssen Biotech, Inc. | $689.12 | 31 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $409.66 | 31 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $398.43 | 30 | $0 (2023) |
| PFIZER INC. | $354.82 | 29 | $0 (2020) |
| UCB, Inc. | $231.92 | 11 | $0 (2020) |
| IRONWOOD PHARMACEUTICALS, INC | $227.39 | 14 | $0 (2020) |
| Braintree Laboratories, Inc. | $224.97 | 10 | $0 (2021) |
| Synergy Pharmaceuticals Inc | $207.50 | 13 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $647.63 | 30 | Janssen Biotech, Inc. ($163.25) |
| 2023 | $721.38 | 29 | ABBVIE INC. ($313.12) |
| 2022 | $370.37 | 14 | Gilead Sciences, Inc. ($136.26) |
| 2021 | $428.34 | 20 | Janssen Biotech, Inc. ($119.25) |
| 2020 | $1,133 | 62 | AbbVie Inc. ($381.11) |
| 2019 | $1,580 | 97 | AbbVie, Inc. ($335.28) |
| 2018 | $2,485 | 83 | AbbVie, Inc. ($1,377) |
| 2017 | $1,352 | 74 | AbbVie, Inc. ($449.77) |
All Payment Transactions
409 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.60 | General |
| 12/13/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/10/2024 | EVOKE PHARMA, INC. | GIMOTI (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Gastroenterology | ||||||
| 11/26/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: LIVER DISEASE | ||||||
| 11/11/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/01/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/30/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $8.97 | General |
| Category: Immunology | ||||||
| 10/22/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/23/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $35.78 | General |
| Category: Immunology | ||||||
| 09/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.28 | General |
| 08/08/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: ENDOCRINOLOGY | ||||||
| 08/01/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Iron Deficiency Anemia | ||||||
| 07/18/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: Iron Deficiency Anemia | ||||||
| 07/11/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $28.86 | General |
| Category: IMMUNOLOGY | ||||||
| 06/29/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Education | In-kind items and services | $84.00 | General |
| Category: Immunology | ||||||
| 06/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: INTERNAL MEDICINE | ||||||
| 06/27/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Iron Deficiency Anemia | ||||||
| 06/06/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.49 | General |
| 05/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: INTERNAL MEDICINE | ||||||
| 05/01/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Iron Deficiency Anemia | ||||||
| 04/19/2024 | Sandoz Inc. | HYRIMOZ (Biological) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: Immunology | ||||||
| 03/27/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Iron Deficiency Anemia | ||||||
| 03/14/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: ENDOCRINOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 904 | 1,116 | $1.2M | $103,873 |
| 2022 | 16 | 1,070 | 1,319 | $1.3M | $118,179 |
| 2021 | 17 | 1,247 | 1,497 | $1.4M | $138,795 |
| 2020 | 16 | 1,052 | 1,221 | $1.1M | $108,849 |
All Medicare Procedures & Services
70 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 245 | 387 | $137,772 | $31,879 | 23.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 73 | 74 | $128,538 | $12,261 | 9.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 93 | 95 | $200,925 | $10,990 | 5.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 51 | 53 | $122,748 | $10,063 | 8.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 129 | 136 | $223,992 | $8,759 | 3.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 51 | 51 | $21,573 | $5,526 | 25.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 41 | 88 | $19,272 | $5,134 | 26.6% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 39 | 42 | $119,532 | $4,233 | 3.5% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 23 | 24 | $41,688 | $3,934 | 9.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 42 | 45 | $18,360 | $3,490 | 19.0% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 27 | 27 | $46,899 | $3,222 | 6.9% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 21 | 22 | $30,580 | $1,450 | 4.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $5,548 | $1,417 | 25.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 15 | $3,660 | $874.36 | 23.9% |
| 45381 | Injection beneath lining of large bowel using a flexible endoscope | Facility | 2023 | 25 | 27 | $55,296 | $336.71 | 0.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 11 | 11 | $1,551 | $304.16 | 19.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 260 | 404 | $136,956 | $33,145 | 24.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 73 | 77 | $170,016 | $14,649 | 8.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 126 | 128 | $258,048 | $13,472 | 5.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 59 | 59 | $97,704 | $10,107 | 10.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 142 | 147 | $230,790 | $9,427 | 4.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 65 | 128 | $26,752 | $6,857 | 25.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 57 | 57 | $22,971 | $5,699 | 24.8% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 34 | 35 | $57,960 | $4,512 | 7.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 47 | 47 | $18,283 | $4,388 | 24.0% |
About Dr. Mario Garretto, MD
Dr. Mario Garretto, MD is a Internal Medicine healthcare provider based in Kenosha, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497701809.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mario Garretto, MD has received a total of $8,717 in payments from pharmaceutical and medical device companies, with $647.63 received in 2024. These payments were reported across 409 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($7,563).
As a Medicare-enrolled provider, Garretto has provided services to 4,273 Medicare beneficiaries, totaling 5,153 services with total Medicare billing of $469,697. Data is available for 4 years (2020–2023), covering 70 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Gastroenterology
- Location Kenosha, WI
- Active Since 05/26/2006
- Last Updated 03/13/2008
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1497701809
Products in Payments
- Humira (Biological) $1,157
- STELARA (Biological) $744.92
- Epclusa (Drug) $551.18
- Mavyret (Drug) $374.51
- XELJANZ (Drug) $290.34
- XIFAXAN (Drug) $283.64
- Entyvio (Biological) $270.83
- MAVYRET (Drug) $251.20
- LINZESS (Drug) $241.60
- Cimzia (Drug) $231.92
- SKYRIZI (Biological) $226.76
- Trulance (Drug) $207.50
- RINVOQ (Biological) $158.58
- LINX Reflux Management System (Device) $148.43
- Creon (Drug) $146.03
- TRULANCE (Drug) $140.39
- INJECTAFER (Drug) $140.28
- CREON (Drug) $132.62
- ENTYVIO (Biological) $129.75
- ZEPOSIA (Drug) $122.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Kenosha
Dr. Hasnain Bawaadam, M.d., M.p.h, M.D., M.P.H
Internal Medicine — Payments: $473,003
Alfred Habel, Md, MD
Internal Medicine — Payments: $223,905
Rosanna Ranieri, Md, MD
Internal Medicine — Payments: $64,322
Dr. Sudip Ringwala, D.o, D.O
Internal Medicine — Payments: $6,114
Dr. Rodrigo Mata, M.d, M.D
Internal Medicine — Payments: $5,201
Stefanie Ruffolo, M.d, M.D
Internal Medicine — Payments: $4,858